Yesterday, Jan 9, 2011, St. Jude Medical announced preliminary revenue results for the fourth quarter ended December 31, 2011:
“Fourth quarter cardiac rhythm management sales were approximately $728 million, a 4 percent decrease compared with the fourth quarter of 2010. Fourth quarter sales of implantable cardiac defibrillators were approximately $436 million, a 5 percent decrease from the comparable quarter in 2010. Pacemaker sales during the quarter were approximately $292 million, a 4 percent decrease compared with the fourth quarter of 2010.
…
Fourth quarter sales of neuromodulation products were approximately $121 million, a 12 percent increase compared to the fourth quarter of 2010.”
Company website: www.sjm.com


I apologize for yesterday’s interruption of service in this blog. I moved hosting company because the old one was too slow and unreliable.



Nanowattics was founded in 2007 to provide development services of ultra-low-power application-specific integrated circuits (ASICs) for safety-critical applications.



One of the indicators of metabolic demand that has been used for controlling the rate of pacemakers is central venous blood temperature (CVT).
